Extracorporeal Membrane Oxygenation versus Conventional Ventilator Support in COVID-19 Patients with Acute Respiratory Distress Syndrome

Kumpoo Foofuengmonkolkit¹, Attapoom Susupaus², Jamorn Udomkusonsri², Tanuntorn Songdechakraiwut², Jule Namchaisiri³, Pranya Sakiyalak⁴

Affiliation : ¹ Cardiovascular and Thoracic Surgery Unit, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand; ² Bangkok Heart Hospital, Bangkok Dusit Medical Services, Bangkok, Thailand; ³ Cardiovascular and Thoracic Surgery Unit, Department of Surgery, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand; ⁴ Division of Cardio-Thoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Background: Acute respiratory distress syndrome (ARDS) is an undesirable outcome of severe coronavirus disease 2019 (COVID-19). Although venovenous extracorporeal membrane oxygenation (VV-ECMO) has been widely accepted as a rescue therapy for severe ARDS, its use in COVID-19-associated ARDS is still debated.
Objective: To compare the clinical outcomes of COVID-19 patients treated with VV-ECMO or conventional ventilator support.
Materials and Methods: The authors conducted a retrospective study in Bangkok Heart Hospital, Thailand, between March and September 2021. Patients were divided into ECMO and non-ECMO or conventional ventilator support groups. The primary outcome was in-hospital mortality, and the secondary outcomes were complications, length of ICU stay, recovery time after extubation, and total length of hospital stay.
Results: Of the 3,053 COVID-19 patients, 36 (1.18%) developed severe ARDS, which 12 were treated with VV-ECMO and 24 with a conventional ventilator. In-hospital mortality was non-significantly lower in the ECMO group at 58.3% versus 83.3% (p=0.126). Upper gastrointestinal bleeding was non-significantly more common in the ECMO group at 41.7% versus 25.0% (p=0.306) but there were no cases of deep vein thrombosis in the ECMO group at 0% versus 20.8% (p=0.088). There were no significant differences in any other complications. Six patients, including four in the ECMO group and two in the non-ECMO group underwent cytokine removal via HA330 hemoperfusion, but interleukin-6 did not decrease in these patients.
Conclusion: VV-ECMO in COVID-19-associated ARDS patients did not significantly decreased mortality compared to conventional ventilator therapy. A multidisciplinary team should develop an optimal treatment plan for each COVID-19-associated ARDS patient.

Keywords : SARS-CoV-2; Intensive care unit, Artificial respiration

All Articles Download

Information

Related Links